Diaz-Galvan et al. (2024) investigated plasma markers across the clinical spectrum of LBD, including iRBD, MCI-LB and DLB patients, and they found that GFAP was elevated early (MCI‐LB) and correlated with amyloid PET positivity, while NfL rose significantly in full-blown DLB [76]. The gene discussed is GFAP; the disease is Lewy body dementia.